The use of brincidofovir for the treatment of mixed dsDNA viral infection

Jose F. Camargo; Michele I. Morris; Lilian M. Abbo; Jacques Simkins; Seyyedeh Saneeymehri; Maritza C. Alencar; Lazaros J. Lekakis; Krishna V. Komanduri

doi:10.1016/j.jcv.2016.07.021

The use of brincidofovir for the treatment of mixed dsDNA viral infection

Jose F. Camargo, Michele I. Morris, Lilian M. Abbo, Jacques Simkins, Seyyedeh Saneeymehri, Maritza C. Alencar, Lazaros J. Lekakis, Krishna V. Komanduri

Medicine

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Double-stranded DNA (dsDNA) viral infections constitute a major complication following solid organ and stem cell transplantation. Few therapeutic options are currently available for the treatment of such infections in highly immunocompromised hosts. Brincidofovir is an oral investigational drug with broad antiviral activity against dsDNA viruses in vitro, but clinical experience is limited. Here we report a young female who developed a mixed infection with adenovirus, cytomegalovirus, Epstein–Barr virus and BK polyomavirus after an allogeneic stem cell transplant, and was successfully treated with brincidofovir.

Original language	English (US)
Pages (from-to)	1-4
Number of pages	4
Journal	Journal of Clinical Virology
Volume	83
DOIs	https://doi.org/10.1016/j.jcv.2016.07.021
State	Published - Oct 1 2016

Keywords

Adenovirus
BK virus
Brincidofovir
CMX001
Cytomegalovirus
Epstein–Barr virus

ASJC Scopus subject areas

Virology
Infectious Diseases

Access to Document

10.1016/j.jcv.2016.07.021

Cite this

@article{69941d17f44440a3bdd428eef24c7dd5,

title = "The use of brincidofovir for the treatment of mixed dsDNA viral infection",

abstract = "Double-stranded DNA (dsDNA) viral infections constitute a major complication following solid organ and stem cell transplantation. Few therapeutic options are currently available for the treatment of such infections in highly immunocompromised hosts. Brincidofovir is an oral investigational drug with broad antiviral activity against dsDNA viruses in vitro, but clinical experience is limited. Here we report a young female who developed a mixed infection with adenovirus, cytomegalovirus, Epstein–Barr virus and BK polyomavirus after an allogeneic stem cell transplant, and was successfully treated with brincidofovir.",

keywords = "Adenovirus, BK virus, Brincidofovir, CMX001, Cytomegalovirus, Epstein–Barr virus",

author = "Camargo, {Jose F.} and Morris, {Michele I.} and Abbo, {Lilian M.} and Jacques Simkins and Seyyedeh Saneeymehri and Alencar, {Maritza C.} and Lekakis, {Lazaros J.} and Komanduri, {Krishna V.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier B.V.",

year = "2016",

month = oct,

day = "1",

doi = "10.1016/j.jcv.2016.07.021",

language = "English (US)",

volume = "83",

pages = "1--4",

journal = "Journal of Clinical Virology",

issn = "1386-6532",

publisher = "Elsevier",

}

TY - JOUR

T1 - The use of brincidofovir for the treatment of mixed dsDNA viral infection

AU - Camargo, Jose F.

AU - Morris, Michele I.

AU - Abbo, Lilian M.

AU - Simkins, Jacques

AU - Saneeymehri, Seyyedeh

AU - Alencar, Maritza C.

AU - Lekakis, Lazaros J.

AU - Komanduri, Krishna V.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Double-stranded DNA (dsDNA) viral infections constitute a major complication following solid organ and stem cell transplantation. Few therapeutic options are currently available for the treatment of such infections in highly immunocompromised hosts. Brincidofovir is an oral investigational drug with broad antiviral activity against dsDNA viruses in vitro, but clinical experience is limited. Here we report a young female who developed a mixed infection with adenovirus, cytomegalovirus, Epstein–Barr virus and BK polyomavirus after an allogeneic stem cell transplant, and was successfully treated with brincidofovir.

AB - Double-stranded DNA (dsDNA) viral infections constitute a major complication following solid organ and stem cell transplantation. Few therapeutic options are currently available for the treatment of such infections in highly immunocompromised hosts. Brincidofovir is an oral investigational drug with broad antiviral activity against dsDNA viruses in vitro, but clinical experience is limited. Here we report a young female who developed a mixed infection with adenovirus, cytomegalovirus, Epstein–Barr virus and BK polyomavirus after an allogeneic stem cell transplant, and was successfully treated with brincidofovir.

KW - Adenovirus

KW - BK virus

KW - Brincidofovir

KW - CMX001

KW - Cytomegalovirus

KW - Epstein–Barr virus

UR - http://www.scopus.com/inward/record.url?scp=84982803413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982803413&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2016.07.021

DO - 10.1016/j.jcv.2016.07.021

M3 - Article

C2 - 27513204

AN - SCOPUS:84982803413

VL - 83

SP - 1

EP - 4

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

ER -

The use of brincidofovir for the treatment of mixed dsDNA viral infection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this